Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Violin I posted
RNS from scope trial on Melanoma Canada CEO Falyn Katz LinkedIn page ?
Maybe we need to send the other reporting journalists this news ?
As I said today Moderna have the trumpets out we are at the silent 🤫 disco
Clearly, they have a great Pr machine . One would maybe consider a good time to get something in the media about the “ trailblazing “ Scancell melanoma vaccine.
When will the new PR company be given the green light ?
https://globalnews.ca/news/10170629/moderna-melanoma-vaccine/
Extract:
It’s huge’: Vaccine for melanoma found to reduce recurrence, death by half
“It’s huge,” Melanoma Canada CEO Falyn Katz told Global News of the announcement. “This is a breakthrough
Seems a rush from Moderna before something better comes out for Melanoma ?
Listen to to the you tube link . Moderna has the Trumpets out . Merck are having a silent disco on the matter
https://amp.theguardian.com/business/2023/jun/20/designing-a-vaccine-that-covers-all-cancers-is-hard-biotech-pioneer-lindy-durrant
This is a very confident article and points to a way forward
Moderna vaccine whilst may have approved in 2025, it will be very expensive???? for insurance companies? Are therefore think that even if Scancell gets approval later than that it’s going to be more beneficial
Ah ok thanks Bermuda for the Clarity . Understandable it’s confusing 🫤
A reminder goes back to 2010 ?
Scancell licenses key ImmunoBody® patents from Merck Serono
Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody® platform, is pleased to announce it has signed a licensing agreement with Merck KGaA, Darmstadt, Germany, acting for its division Merck Serono, for two key patents required for the further development and commercialisation of protein ImmunoBody® vaccines. Under the agreement, Scancell has non-exclusive worldwide rights to use the two patents to further develop and commercialise ImmunoBody® vaccines in all therapeutic areas in both humans and animals.
In addition, Scancell has granted Merck Serono an option to negotiate an exclusive license under Scancell's ImmunoBody® platform technology for up to five Merck Serono targets.
Scancell's ImmunoBody® is a breakthrough patent-protected platform technology that aims to overcome the current limitations of cancer vaccines by generating the high-avidity T-cells that kill cancer cells.
By re-engineering the vector, the Immunobody® platform technology can be adapted to provide the basis for treating any tumour type and may also be of utility in the development of vaccines against chronic infectious diseases including hepatitis and HIV.
Scancell's first cancer vaccine SCIB1 is being developed to treat melanoma, with clinical trials commencing in 2010.
David Evans, chairman of Scancell, commented:
"We are delighted to have forged this association with Merck Serono. The agreement will add further strength to Scancell's IP position, as it continues to progress its development of therapeutic vaccines based on the Immunobody® platform."
This is worth a watch wait until after the adverts
seems company split on opinion Merck v Moderna
either way suspect both these companies are watching Scancell
https://www.youtube.com/watch?v=9PfJVkO3s5I
Https://academic.oup.com/discovimmunology/article/2/1/kyac011/6874811
Who said at the AGM Lindy Durrant mentioned , after she had delivered her speech at the vaccine congress some one said from Moderna either " It works were, were in trouble '? or " it works we are in trouble " ?
Lots of buys this morning at 11p , ja question for those who attended the AGM. There was going to be an evaluation of a cell therapy company within six months ( presume now completed )did anybody ask the question about this company ?
results from Modi 1 and melanoma vaccine, should be soon and to see when Mandeep's first deal will come through it's getting rather exciting
Yes all to play for ? Avidimab took up my full allowance. Roll on more results x
It’s a funny old world when the share price is now below offer price but them now , I would say ?
What’s the opinions on the share offer ?
Very interesting article , people in certain places are talking about Scancell . however I am very surprised nothing at all in the general media , come on new Pr company earn your fee unless gearing up for the big reveal ? good luck to one an all
https://calculuscapital.com/elizabeth-klein-quoted-in-forbes-how-to-invest-in-healthcare/
Burble many thanks for the excellent explanation
2 minutes in the Glycolsation ( spelling not my strong point ) pops up worth watching
Just wondering if Glymab has been used in the Duobody platform this latest video
https://www.youtube.com/watch?v=M7-DRxjT1gk
Hi Max "What will happen in the next 24 month !"
There will be a lot of happy patients and families spending more time with loved ones XX
A lot , much much more than -12p
Marcusl2: Market cap ÂŁ109m
scib-1
Melanoma 85% ORR
Modi-1
negative breast (TNBC),
ovarian,
renal,
head & neck cancer
and soon doublet in Liver Hepatocellular carcinoma. (HCC
SC129
pancreatic / colorectal
Modi-2
Multiple solid tumours
Aldolase (like α-enolase) is a glycolytic protein which is highly expressed in a number of cancers and upregulation of the aldolase gene has also been linked to poor prognosis in colon cancer, renal cell carcinoma and colorectal cancer.
Keratins are the largest family of intermediate filament proteins and have a wide tissue distribution, multiple functions and disease associations. Cytokeratin expression, along with the cytoskeletal protein vimentin, results in increased invasion and metastasis in breast cell carcinomas and melanomas.
BiP is preferentially expressed on the surface of stressed cancer cells, where it is involved in the regulation of critical oncogenic signalling pathways.
NPM plays a variety of roles in cellular metabolism and overexpression of NPM has been reported in multiple human cancers including those of the pancreas, prostate, liver, colon, stomach and thyroid.
High expression levels of HSP60 have been noted in several cancers; it favours the survival of certain types of tumour cells and, in some cases, may be essential for tumour-cell growth.
Scib-2
The SCIB2/iSCIB2 vaccine is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC)
Scib-3
?
Modi-3
?
SC134 • TCB lead target • Fucosyl GM1 • Small cell lung cancer
SC2811 • Stimulatory mAb target SSEA4 • Any solid tumour
SC88 • Lewisacx • Colorectal cancer
SC27 • Lewisy • Ovarian cancer
Further Glymabs being worked on in the lab
Avidimab
• Engineer the anti-glycan mAbs to improve their ability to directly kill tumour cells.
• Engineer other mAbs to enhance their potency and/or extend their patent lifetime.
• Increase the breadth of response and potency of Scancell’s ImmunoBody® cancer products.
• Increase the potency of the T cell response in Scancell’s COVID-19 vaccine which in turn should lead to improvements in long-term protection and immunological memory.
We are in negotiations with numerous potential partners.
Funded until 2025
All this money and it’s Pre clinical?
Thinking aloud how many melanoma trials will be made redundant by the Scope trial
https://www.businesswire.com/news/home/20231205177324/en/Odyssey-Therapeutics-Announces-101-Million-Series-C-Financing
Odyssey has rapidly advanced a portfolio of immunology and oncology therapeutics with the goal of providing transformative medicines for large numbers of patients in need and several of these molecules have the potential to enter the clinic in the next 12 months,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey. “For us, success is defined as bringing safe and effective medicines to patients with serious diseases, with support from Ascenta and our other investors driving our pipeline into the future. We welcome Dr. Lorence Kim, co-founder and managing partner of Ascenta Capital, to our board to join us in achieving this mission.”